Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development stra...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rico, María José, Baglioni, María, Bondarenko, Maryna, Laluce, Nahuel Cesatti, Rozados, Viviana R., André, Nicolas, Carré, Manon, Scharovsky, O. Graciela, Márquez, Mauricio Menacho
Formato: article artículo publishedVersion
Lenguaje:Inglés
Publicado: Rapamycin Press 2018
Materias:
Breast cancer
Metronomics
Drug repositioning
Metformin
Propranolol
Acceso en línea:http://hdl.handle.net/2133/11407
http://hdl.handle.net/2133/11407
Aporte de:
Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario
id I15-R121-2133-11407
record_format dspace
institution Universidad Nacional de Rosario
institution_str I-15
repository_str R-121
collection Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR)
language Inglés
orig_language_str_mv eng
topic Breast cancer
Metronomics
Drug repositioning
Metformin
Propranolol
spellingShingle Breast cancer
Metronomics
Drug repositioning
Metformin
Propranolol
Rico, María José
Baglioni, María
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana R.
André, Nicolas
Carré, Manon
Scharovsky, O. Graciela
Márquez, Mauricio Menacho
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
topic_facet Breast cancer
Metronomics
Drug repositioning
Metformin
Propranolol
description Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.
format article
artículo
publishedVersion
author Rico, María José
Baglioni, María
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana R.
André, Nicolas
Carré, Manon
Scharovsky, O. Graciela
Márquez, Mauricio Menacho
author_facet Rico, María José
Baglioni, María
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana R.
André, Nicolas
Carré, Manon
Scharovsky, O. Graciela
Márquez, Mauricio Menacho
author_sort Rico, María José
title Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_short Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_full Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_fullStr Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_full_unstemmed Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_sort metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
publisher Rapamycin Press
publishDate 2018
url http://hdl.handle.net/2133/11407
http://hdl.handle.net/2133/11407
work_keys_str_mv AT ricomariajose metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT baglionimaria metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT bondarenkomaryna metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT lalucenahuelcesatti metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT rozadosvivianar metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT andrenicolas metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT carremanon metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT scharovskyograciela metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
AT marquezmauriciomenacho metforminandpropranololcombinationpreventscancerprogressionandmetastasisindifferentbreastcancermodels
bdutipo_str Repositorios
_version_ 1764820408879546369

Ejemplares similares